Pegargiminase + Chemo Increases Survival Rate in Nonepithelioid Pleural Mesothelioma
Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy
Disparities in Transgender Prostate Screening Uptake Driven by Clinicians
Clinician-led recommendations for and discussions of PSA screening explained differences between cisgender and transgender screening rates
Poll Shows Strong Support Among Black Voters for Menthols Ban
Rusfertide Treatment Beneficial for Patients With Polycythemia Vera
Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent
Review: Menthol Cigarette Bans Promote Smoking Cessation
24 percent of menthol cigarette smokers quit smoking after menthol ban; 50 percent switch to nonmenthol cigarettes
Jill Biden Announces $100 Million for Research on Women’s Health
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
Overall survival inferior for acute myeloid leukemia patients with versus without central nervous system involvement
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
This Election Year, Health Care Costs Top Voter Concerns: Poll
Amtagvi Approved by the FDA for Treatment of Advanced Melanoma
Agency approves one-time cell therapy for patients who have progressed after initial standard-of-care therapies
